- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04058054
Skin Prick Test of KeraStat® Cream
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Overview:
Study Periods:
The length of study participation for a subject is about 2-3 days depending on availability for the final site check. There are two skin prick site checks during the course of Day 1 with a final follow up between Days 2 and 3.
Study Evaluations:
Initial screening (Screening Visit; Visit 1) will be performed on the day of the Skin Prick Test (SPT) administration and will include obtaining demographic information, brief medical history, and abbreviated physical exam.
On Day 1 (Visit 1) the SPT will be performed on the infrascapular region of the back to the right of the midline. Test articles will include the subject device (KeraStat Cream), predicate devices (KeraStat Gel, Biafine), positive control (histamine), and negative control (saline). Each test article will have a single administration, only the re-test will utilize a triplicate administration. The SPT will be ready for initial reading after approximately 15 minutes (but no sooner than 10 minutes and no longer than 20 minutes) following the final SPT administration in the series. When reading the test, the investigator will note the presence or absence of a wheal at all five sites and will measure the diameter of each wheal present. In order for the SPT to be valid, the wheal at the positive control site must exceed that at the negative control by 4 mm. If the above criteria are not met, the SPT will be repeated in triplicate on the infrascapular region of the back to the left of the midline, following the same protocol. Following the initial reading, the subject will remain at the testing facility.
A second reading will be conducted approximately 6 hours (+/- 15 minutes) after SPT administration on Day 1 (Visit 1). When reading the test, the investigator will note the presence or absence of a wheal at all five sites and will measure the diameter of each wheal present. Subjects are free to leave the clinical site after the second reading. Subjects will be instructed to promptly contact the PI and go to the ER if symptoms of an allergic reaction or shock occur.
Subjects will return to the office one to two days after initial administration for a third test reading (Visit 2). When reading the test, the investigator will note the presence or absence of a wheal in all five sites and will measure the diameter of each wheal present. Each site of test article administration will be measured for a positive reaction. A positive reaction is present when there is a measurable wheal of 3 mm or more, surrounded by a flare. Small wheals are to be confirmed by palpation. A flare alone is disregarded.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27103
- PMG Research, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women, age 18-65
- Able to understand the informed consent and provide written informed consent
- Healthy, unmarked skin at the test area
- Agreement to avoid consumption of antihistamines until completion of third test reading (Visit 2)
Exclusion Criteria:
- Women who are pregnant, lactating/nursing or plan to become pregnant
- Presence of skin disease, such as widespread urticaria or eczema
- Diagnosis of infectious disease
- Receiving corticosteroids, immunosuppressive agents, radiation or chemotherapy, topical growth factors, anxiolytics, imipramine, phenothiazine, dopamine, phenergen, clonidine, montelukast, immunotherapy, UV light therapy, H-2 antagonist, cyclosporine or any other medication the investigator feels will affect the test within the last month
- Medical history of hypotension, severe hypertension, vasomotor instability, asthma, autoimmune disease, severe cardiac, pulmonary or renal disease
- Tattoo in the intrascapular test area
- History of surgical procedure/skin graft in the intrascapular test area
- Employee or relative of employee of KeraNetics
- Consumption of an anti-histamine within 7 days of the screening visit
- History of hypersensitivity to histamine products
- Any condition the investigator determines will compromise subject safety or prevent the subject from completing the study
- Participated in an investigational study within 30 days of the screening visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: KeraStat® Cream
KeraStat® Cream is a non-sterile, non-implantable wound dressing intended to provide a moist environment in the management of a variety of partial thickness dermal wounds.
|
Administered 0.025 gm of KeraStat Cream per subject on day 1 of the study.
|
EXPERIMENTAL: KeraStat® Gel
KeraStat® Gel is a sterile, non-implantable water-based gelatinous (hydrogel) wound dressing intended to act as a protective covering in the management of a variety of partial thickness dermal wounds.
|
Administered 0.025 gm of KeraStat Gel per subject on day 1 of the study.
|
EXPERIMENTAL: Biafine
Wound dressing for management of partial and full thickness wounds.
|
Administered 0.025 gm of Biafine per subject on day 1 of the study.
|
ACTIVE_COMPARATOR: Histamine
Histamine is provided as a solution of histamine base (6.0 mg/mL).
|
Administered 1 drop of Histamine Dihydrocl (6 mg/mL) per subject on day 1 of the study.
|
SHAM_COMPARATOR: Saline
Saline (sterile) is provided as a 0.9% NaCl solution.
|
Administered 1 drop of saline per subject on day 1 of the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reaction to Test Article
Time Frame: assessed at 15 min, 6 hours, 24-48 hours; 15 min reported
|
Wheal measurement in millimeters (mm)
|
assessed at 15 min, 6 hours, 24-48 hours; 15 min reported
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jonathan P Wilson, DO, PMG Research
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KSCM-CRD-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypersensitivity
-
National Institute of Allergy and Infectious Diseases...Consortium of Food Allergy ResearchCompletedMilk Hypersensitivity | Egg Hypersensitivity | Food Hypersensitivity | Peanut HypersensitivityUnited States
-
Ospedale Buon Consiglio FatebenefratelliCompleted- Egg HypersensitivityItaly
-
IRCCS Burlo GarofoloCompleted
-
National Institute of Allergy and Infectious Diseases...Consortium of Food Allergy ResearchCompletedHypersensitivity | Food Hypersensitivity | Peanut Hypersensitivity | Immediate HypersensitivityUnited States
-
Johns Hopkins UniversityCompletedFood Hypersensitivity | Peanut Hypersensitivity | Immediate HypersensitivityUnited States
-
Allertein Therapeutics, LLCConsortium of Food Allergy ResearchCompletedHypersensitivity | Food Hypersensitivity | Peanut Hypersensitivity | Immediate HypersensitivityUnited States
-
University of North Carolina, Chapel HillWithdrawnNut Hypersensitivities
-
Alton MeltonThe Cleveland ClinicActive, not recruiting
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)Completed
-
National Institute of Allergy and Infectious Diseases...Consortium of Food Allergy ResearchCompletedHypersensitivity | Food Hypersensitivity | Hypersensitivity, Immediate | Peanut HypersensitivityUnited States
Clinical Trials on KeraStat® Cream
-
KeraNetics, LLCCompleted
-
The Metis FoundationRecruitingBurns | Wound of SkinUnited States
-
Shanghai Zhongshan HospitalRecruiting
-
KK Women's and Children's HospitalNot yet recruiting
-
Loreal USACompleted
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); KeraNetics, LLCCompletedHead and Neck Cancer | Radiation DermatitisUnited States
-
University of Roma La SapienzaCompleted
-
Pharmanutra S.p.a.NEA Clinical S.r.l.Active, not recruitingAnkle Injury or Chronic Trauma to the AnkleGeorgia, Italy
-
Dermavant Sciences, Inc.Completed
-
LEO PharmaCompletedPsoriasis VulgarisCanada